Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 154 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ocular Pain Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluate the TetraLens, a Tetracaine Releasing Therapeutic Bandage Contact Lens in Patients Undergoing PRK Procedure

NCT06085352
View directory record Official record
Conditions
Ocular Pain
Interventions
TetraLens bandage contact lens, Control Acuvue Oasys Bandage contact Lens
Drug · Device
Lead sponsor
Vance Thompson Vision
Other
Eligibility
22 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Phase 3 Interventional

Evaluation of Vitrase as a Spreading Agent

NCT00198484
View directory record Official record
Conditions
Pain
Interventions
Vitrase
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
18
States / cities
Newport Beach, California • Sacramento, California • Littleton, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 21, 2026, 3:47 PM EDT
Terminated Not applicable Interventional Results available

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

NCT00726830
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Spartanburg, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study

NCT04810962
View directory record Official record
Conditions
Ocular Inflammation and Pain After Cataract Surgery
Interventions
APP13007, 0.05%, Matching Vehicle Placebo for APP13007, 0.05%
Drug
Lead sponsor
Formosa Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
31
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 21, 2026, 3:47 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers

NCT06978244
View directory record Official record
Conditions
Ocular Pain
Interventions
BL1332 ophthalmic solution, BL1332 ophthalmic vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Can Virtual Reality Reduce Pain and Anxiety During Blood Draw

NCT04449341
View directory record Official record
Conditions
Procedural Anxiety, Procedural Pain
Interventions
Oculus Go headset with Ocean Rift application
Device
Lead sponsor
C.R.Darnall Army Medical Center
Federal
Eligibility
18 Years to 50 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Fort Hood, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease

NCT02819284
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
909 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
62
States / cities
Birmingham, Alabama • Chandler, Arizona • Jonesboro, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery

NCT04739709
View directory record Official record
Conditions
Ocular Inflammation and Pain
Interventions
APP13007, 0.05%, Matching Vehicle Placebo for APP13007, 0.05%
Drug
Lead sponsor
Formosa Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
34
States / cities
Scottsdale, Arizona • Glendale, California • Hemet, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Phase 4 Interventional Results available

Using Triamcinolone Acetonide to Reduce Pain After Scleral Buckle Surgery

NCT04701593
View directory record Official record
Conditions
Retinal Detachment
Interventions
Triamcinolone Acetonide 40mg/mL
Drug
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
19 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Phase 4 Interventional

Evaluation of Vitrase as an Adjuvant to Increase Absorption and Dispersion of Other Injected Anesthetics

NCT00198549
View directory record Official record
Conditions
Pain
Interventions
Vitrase (ovine hyaluronidase) Lyophilized
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Oct 21, 2026, 3:47 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Phase 4 Interventional

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery

NCT04521140
View directory record Official record
Conditions
Corneal Edema, Corneal Defect, Corneal Transplant, Penetrating KeratoPlasty, Anterior Chamber Inflammation, Ocular Pain, Intraocular Pressure
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
Nicole Fram M.D.
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 21, 2026, 3:47 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

fMRI and IVCM Cornea Microscopy of CXL in Keratoconus

NCT04439552
View directory record Official record
Conditions
Pain, Postoperative, Pain, Chronic, Pain, Acute, Surgical Injury, Surgical Wound, Cornea Injury, Cornea, Keratoconus
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Phase 3 Interventional

A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract

NCT04539548
View directory record Official record
Conditions
Cataract
Interventions
Dextenza Ophthalmic Insert, Prednisolone acetate ophthalmic suspension USP 1%
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
0 Years to 5 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
14
States / cities
Aurora, Colorado • Fort Collins, Colorado • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Phase 2 Interventional Results available

RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

NCT02065375
View directory record Official record
Conditions
Inflammation and Pain Following Ocular Surgery
Interventions
Omaveloxolone Ophthalmic Suspension 1.0%, Omaveloxolone Opthalmic Suspension 0.5%, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Fort Myers, Florida • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 21, 2026, 3:47 PM EDT
Terminated Not applicable Interventional Results available

Spectacle Tints and Thin-Films for Migraine

NCT02720211
View directory record Official record
Conditions
Headache Migraine Chronic
Interventions
Gray tinted spectacle lenses, Thin-Film spectacle lenses
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Phoenix, Arizona • Boston, Massachusetts • Great Neck, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 21, 2026, 3:47 PM EDT
Terminated Phase 4 Interventional

Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections

NCT04563299
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate
Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Phase 3 Interventional Results available

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)

NCT04246801
View directory record Official record
Conditions
Cataract
Interventions
Clobetasol propionate, Vehicle
Drug
Lead sponsor
Salvat
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
22
States / cities
Chandler, Arizona • Beverly Hills, California • Glendora, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF)

NCT05747430
View directory record Official record
Conditions
Retinal Disease
Interventions
IRX-101, Providone-Iodine
Drug
Lead sponsor
iRenix Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
7
States / cities
Greenwich, Connecticut • Madison, Mississippi • Erie, Pennsylvania + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 21, 2026, 3:47 PM EDT
Enrolling by invitation Phase 3 Interventional

A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery

NCT07832552
View directory record Official record
Conditions
Postoperative Ocular Inflammation, Postoperative Ocular Pain
Interventions
Sham (No Treatment), TRIESENCE (triamcinolone acetonide injectable suspension)
Procedure · Drug
Lead sponsor
Harrow Inc
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Discomfort Associated With Scleral Depression During Retina Examinations

NCT04115917
View directory record Official record
Conditions
Retina--Diseases, Retinal Detachment, Retinal Degeneration
Interventions
Schocket scleral depressor, Cotton tipped applicator
Device
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 21, 2026, 3:47 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Human Behaviors Related to the Expectation of Pain

NCT03739645
View directory record Official record
Conditions
Fear Pain
Interventions
Skin conductance levels and slopes over time in conditioned fear as metrics.as metrics for anxiety
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
16 Years to 88 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 21, 2026, 3:47 PM EDT
Terminated Phase 4 Interventional Results available

Does Topical Ophthalmic Anesthetic Prior to Probing and Irrigation Decrease Pain?

NCT04229771
View directory record Official record
Conditions
Epiphora, Dacryostenosis, Dacryocystitis
Interventions
Proparacaine Hydrochloride ophthalmic solution, USP 0.5%, Balanced salt solution
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 21, 2026, 3:47 PM EDT
Terminated Phase 3 Interventional Results available

Surgical Idiopathic Intracranial Hypertension Treatment Trial

NCT03501966
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Acetazolamide, Optic Nerve Sheath Fenestration, Ventriculoperitoneal CSF Shunting
Drug · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 63 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
33
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2022 · Synced Oct 21, 2026, 3:47 PM EDT